No Big Surprise For Novartis: Prexige Is “Not Approvable” At FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm now plans to discuss path forward, which may include additional trials of the COX-2 inhibitor, with FDA, Novartis tells "The Pink Sheet" DAILY.
You may also be interested in...
PPI/NSAID Combinations Could Have Smoother Route To Approval After Review Division Harmonization
FDA will ask its Gastrointestinal Drugs Advisory Committee at a Nov. 4 meeting whether it agrees that endoscopically diagnosed ulcers are an appropriate surrogate endpoint, which would make large, pre-approval GI outcomes studies unnecessary.
PPI/NSAID Combinations Could Have Smoother Route To Approval After Review Division Harmonization
FDA will ask its Gastrointestinal Drugs Advisory Committee at a Nov. 4 meeting whether it agrees that endoscopically diagnosed ulcers are an appropriate surrogate endpoint, which would make large, pre-approval GI outcomes studies unnecessary.
Novartis Eyes Liver Safety Biomarker As Potential Path To Prexige Approval
Novartis has identified a genetic sequence that may be a risk factor for serious liver injury in patients receiving Prexige (lumiracoxib), a finding that may signal a development path forward for the COX-2 inhibitor